● Live
Tracking psychedelic news in real time — 100 articles loaded
A self-hosted psychedelic industry intelligence dashboard — live news, clinical trial tracking, and regulatory monitoring, aggregated from public sources. How it works →
Article summaries below are AI-generated and may contain inaccuracies — verify against the linked source before relying on them.
Culture
The Oldest Ayahuasca Researchers Weren’t in Labs
DoubleBlind · Sep 23, 2026
Culture
Reflections on the Psychedelic Executive Order: The Dust Settles
Chacruna · Sep 23, 2026
Culture
Building Tripsafe Communities: Why We Need Psychedelic Harm Reduction
Chacruna · Sep 23, 2026
Business
Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
Psychedelic Alpha · Sep 21, 2026
Business
Introducing The Psychedelic News Feed Podcast
Psychedelic Alpha · Sep 21, 2026
Culture
Psychedelic Therapy Is Imminent. Will the FDA Get It Right?
DoubleBlind · Sep 21, 2026
Business
Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
AI summary
Psychedelics Week in Washington D.C. brought together industry leaders, researchers, and policymakers to discuss regulatory advancements, clinical research, and the future of psychedelic integration. Key discussions highlighted bipartisan support for therapeutic applications and the need for standardized frameworks to accelerate access and safety. The event underscored growing momentum for policy reform and cross-sector collaboration in the psychedelic space.
Psychedelic Alpha · Sep 18, 2026
Culture
Conjuring Giant Sphinxes at Burning Man to Help You Know Yourself
AI summary
The article explores how psychedelic-inspired art installations, such as giant Sphinx sculptures at Burning Man, are used to foster self-reflection and spiritual exploration, highlighting the intersection of psychedelic experiences and immersive cultural events. These creations aim to catalyze introspection and personal growth through symbolic, transformative art. The piece underscores growing interest in integrating psychedelic practices with creative and communal experiences within the broader psychedelic industry.
DoubleBlind · Sep 18, 2026
Business
‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
AI summary
ARPA-H’s Ibogaine Workshop emphasized the need for rapid, precise advancements in psychedelic research to accelerate safe, scalable therapeutic applications. Key discussions centered on prioritizing clinical trials, regulatory strategies, and cross-sector collaboration to address challenges in translating ibogaine’s potential into FDA-approved treatments. Stakeholders highlighted the importance of balancing innovation with rigorous scientific standards to ensure patient safety and efficacy.
Psychedelic Alpha · Sep 17, 2026
Policy
What Lynn Watkins Actually Told the FDA about Chronic Pain and Psychedelics
AI summary
Lynn Watkins provided the FDA with detailed insights into her clinical research on psychedelics for chronic pain, emphasizing their potential efficacy and safety in treating refractory cases. Her testimony highlighted the need for regulatory clarity and expanded access to psychedelic therapies, sparking discussions on their role in pain management. The exchange underscores growing interest in psychedelics as a viable alternative for chronic pain treatment.
Psychedelics Today · Sep 16, 2026
Business
Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
Psychedelic Alpha · Sep 16, 2026
Culture
The Psychedelic Legacy Africa Still Isn’t Properly Credited For
AI summary
The article highlights how Africa's ancient use of psychedelics in spiritual and cultural practices has been historically overlooked, despite their foundational role in the region's psychedelic legacy. Modern Western commercialization of these substances often fails to credit or collaborate with African communities, raising ethical concerns about appropriation. The piece calls for greater recognition of indigenous knowledge and equitable partnerships in the psychedelic industry.
DoubleBlind · Sep 16, 2026
Business
No Questions Asked: FDA’s Psychedelics Public Hearing
Psychedelic Alpha · Sep 15, 2026
Business
Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
AI summary
Definium has achieved a second positive Phase 3 trial result for its treatment of Generalised Anxiety Disorder, marking a significant milestone in advancing its psychedelic-based therapeutic approach. The success underscores the potential of its formulation to meet regulatory standards and could expedite pathways to market approval. This outcome highlights growing momentum in the psychedelic industry for addressing mental health conditions with novel, evidence-based interventions.
Psychedelic Alpha · Sep 14, 2026
Culture
Scientists Engineered a “Humanized” Mouse to Study Psychedelics
AI summary
Scientists have developed a "humanized" mouse model, engineered to express human serotonin receptors, to better study the biological mechanisms of psychedelics like psilocybin and MDMA. This advancement enables more accurate preclinical research into their therapeutic potential for mental health disorders. The model represents a significant step forward in bridging the gap between animal studies and human applications in psychedelic science.
DoubleBlind · Sep 14, 2026
Culture
Between Protection and Control: Federal Public Prosecutor’s Office Reignites the Debate on Ayahuasca Regulation in Brazil
AI summary
The Brazilian Federal Public Prosecutor’s Office has intensified legal actions against Ayahuasca practitioners, reigniting debates over the drug’s regulation under Brazil’s 2006 law. The move highlights tensions between protecting indigenous traditions and enforcing anti-narcotic controls, with critics warning of risks to cultural and spiritual practices. The case underscores ongoing legal and ethical challenges in balancing public health concerns with the rights of religious communities.
Chacruna · Sep 11, 2026
Business
Approvals to Access: A Crude Schematic
AI summary
Psychedelic Alpha's article "Approvals to Access: A Crude Schematic" outlines the complex regulatory and logistical challenges in scaling psychedelic therapy access, emphasizing the need for streamlined approval processes and stakeholder collaboration to bridge gaps between research and real-world implementation. The piece highlights key bottlenecks in clinical trials, licensing, and distribution, while advocating for a more transparent, patient-centered framework to accelerate therapeutic availability. It underscores the critical role of policy alignment in overcoming systemic barriers to psychedelic medicine.
Psychedelic Alpha · Sep 11, 2026
Culture
Ayahuasca and Wellness Spaces Aren’t Built for Disabled and Autistic Bodies
AI summary
The article highlights systemic accessibility barriers in ayahuasca and wellness spaces, which often fail to accommodate disabled and autistic individuals due to physical, sensory, and communicative challenges. These gaps limit equitable participation in psychedelic healing practices, underscoring the need for inclusive design and support systems in the industry. Advocates call for greater awareness and structural changes to ensure these spaces are accessible to all.
DoubleBlind · Sep 11, 2026
Policy
Beyond the Foxhole: How Psychedelic Policy’s Coalition Is Growing Past Veterans
AI summary
The article highlights the expansion of psychedelic policy advocacy beyond veteran communities, driven by growing support from healthcare professionals, patients, and researchers. This broadening coalition reflects increasing recognition of psychedelics' therapeutic potential and the need for legislative reform to facilitate clinical use and public access. The shift underscores a maturing movement with diverse stakeholders pushing for policy changes.
Psychedelics Today · Sep 11, 2026
Culture
The Case That Shook Céu do Mar
AI summary
The case involving Céu do Mar, a Brazilian psychedelic research center, sparked significant legal and regulatory debate, highlighting tensions between scientific exploration and government oversight in the psychedelic industry. The ruling underscored the complexities of navigating legal frameworks for psychedelic research, influencing ongoing discussions about policy reform and therapeutic applications. This landmark case has since become a pivotal reference point for advocates and policymakers in the global psychedelic movement.
Chacruna · Sep 10, 2026
Policy
THE GATEWAY: Live From DC After the FDA Psychedelics Hearing
AI summary
The FDA's recent psychedelics hearing in DC highlighted ongoing regulatory discussions around therapeutic applications, with officials emphasizing the need for robust clinical data and safety protocols. Key stakeholders expressed cautious optimism about potential pathway advancements, while calls for transparency and equitable access remained central to the dialogue. The event underscored the industry's pivotal role in shaping future psychedelic medicine policies.
Psychedelics Today · Sep 10, 2026
Business
Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
AI summary
In a recent NEJM publication, Davis, Farchione, and colleagues outlined the FDA’s proposed framework for psychedelic drug development, emphasizing structured clinical trial protocols, safety monitoring, and therapeutic applications. The framework aims to standardize regulatory pathways for psychedelics, balancing innovation with patient safety. This guidance marks a pivotal step toward legitimizing psychedelic therapies within mainstream medicine.
Psychedelic Alpha · Sep 10, 2026
Culture
Indigenous Medicines Are Inseparable From Territory
AI summary
The article emphasizes that indigenous medicinal practices are deeply tied to specific territories, reflecting a holistic relationship between people, land, and healing traditions. This connection underscores the ethical and legal complexities for the psychedelic industry, which must navigate issues like biopiracy and cultural appropriation. The piece calls for respectful collaboration with Indigenous communities to ensure their knowledge is preserved and honored.
DoubleBlind · Sep 9, 2026
Business
Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD
AI summary
Two New Zealand psychiatrists have been approved to prescribe MDMA for PTSD treatment, marking a significant milestone in the country's integration of psychedelic-assisted therapies. This development follows regulatory progress and highlights the potential of MDMA as a groundbreaking intervention for trauma-related disorders. The psychiatrists will now lead clinical trials, advancing access to innovative PTSD care in New Zealand.
Psychedelic Alpha · Sep 7, 2026
Culture
Those Trump-Shaped Ecstasy Pills Actually Aren’t Ecstasy At All
AI summary
A recent investigation by DoubleBlind reveals that Trump-shaped pills marketed as ecstasy (MDMA) are not actually MDMA, raising concerns about mislabeling and the potential presence of other substances. The pills, part of a controversial marketing stunt, were found to contain different compounds, highlighting risks in the psychedelic and illicit drug markets. This case underscores the need for stricter regulation and transparency in psychedelic product labeling.
DoubleBlind · Sep 7, 2026
Culture
Is “Gas Station Molly” the Next Big Grey Market Drug?
DoubleBlind · Sep 4, 2026
Business
Pα+ Library: Psychedelic REMS
Psychedelic Alpha · Sep 3, 2026
Culture
Inside the First Ayahuasca Forum Hosted by Indigenous Peoples
AI summary
The first Ayahuasca Forum hosted by Indigenous Peoples, as reported by DoubleBlind, brought together traditional knowledge holders and global stakeholders to discuss the plant's cultural significance, legal challenges, and potential therapeutic applications. The event emphasized Indigenous sovereignty in safeguarding sacred practices while exploring pathways for ethical integration into modern wellness and research frameworks. Participants highlighted the need for respectful collaboration and policy reform to protect both cultural heritage and scientific inquiry.
DoubleBlind · Sep 2, 2026
Business
Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?
Psychedelic Alpha · Sep 1, 2026
Culture
Can Psilocybin Protect Skin Cells From Premature Aging?
DoubleBlind · Sep 1, 2026
Culture
Hidden Treasures: How a Team of Chilean Psychonauts is Preserving Jonathan Ott’s Legacy
AI summary
A Chilean team of psychonauts is collaborating with Chacruna to preserve the ethnobotanical research and writings of Jonathan Ott, a pioneering figure in psychedelic studies, by digitizing and archiving his work to ensure its accessibility and legacy for future generations. Their efforts highlight the importance of safeguarding traditional knowledge and scientific contributions in the psychedelic field. This initiative underscores the intersection of cultural preservation and contemporary research in the industry.
Chacruna · Aug 31, 2026
Culture
Technodelics Promise Psychedelic Healing. Can They Deliver?
AI summary
The article explores the emerging field of technodelics, which combine psychedelic therapies with digital tools to enhance mental health treatment. While proponents highlight their potential for scalable, personalized healing, skeptics question their clinical efficacy and regulatory readiness. The piece underscores the industry's ambitious goals amid ongoing debates about scientific validation and ethical implications.
DoubleBlind · Aug 28, 2026
Policy
The Best Psychedelic Education Does Not Look Psychedelic
AI summary
The article argues that effective psychedelic education prioritizes practical, evidence-based approaches over visually stimulating or "psychedelic" aesthetics, emphasizing structured learning and integration techniques to ensure safe, informed use. It highlights the importance of grounding education in scientific research and therapeutic applications to support the industry's growth and responsible practices. The piece underscores that meaningful education focuses on knowledge and preparation rather than sensory spectacle.
Psychedelics Today · Aug 28, 2026
Business
A Closer Look at Definium’s Phase 3 LSD for GAD Readout
AI summary
Definium’s Phase 3 trial for LSD as a treatment for generalized anxiety disorder (GAD) released preliminary data showing promising efficacy and safety profiles, with significant reductions in anxiety symptoms observed in participants. The results highlight potential regulatory and therapeutic advancements for psychedelic medicine, though further analysis is needed for full conclusions. The findings underscore growing interest in LSD’s role in mental health treatment within the psychedelic industry.
Psychedelic Alpha · Aug 26, 2026
Culture
Was Carlos Castaneda Among the First Psychedelic Grifters?
AI summary
The article explores whether Carlos Castaneda, a controversial figure in 20th-century spirituality, misrepresented his experiences with a Yaqui teacher, potentially using psychedelics as a vehicle for personal gain. It questions the authenticity of his accounts, suggesting he may have fabricated elements of his narrative to capitalize on the psychedelic movement's cultural moment. The piece highlights ongoing debates about the intersection of mysticism, exploitation, and the legacy of early psychedelic exploration.
DoubleBlind · Aug 26, 2026
Policy
Who Gets to Heal?
AI summary
The article "Who Gets to Heal?" from Psychedelics Today examines disparities in access to psychedelic therapies, highlighting systemic barriers such as socioeconomic inequality, racial bias, and lack of insurance coverage that limit marginalized communities' ability to benefit from these treatments. It underscores the urgent need for policy reforms and equitable distribution of resources to ensure psychedelic healing is accessible to all, not just those with financial privilege. The piece calls for industry stakeholders to prioritize inclusivity and address historical inequities in mental health care.
Psychedelics Today · Aug 25, 2026
Culture
Queering Psychedelics
AI summary
The article "Queering Psychedelics" from Chacruna explores the increasing integration of LGBTQ+ perspectives into psychedelic research and practice, emphasizing the role of queer narratives in redefining cultural, spiritual, and therapeutic frameworks within the field. It highlights the importance of creating inclusive spaces that honor diverse identities and experiences, advocating for intersectional approaches to ensure equity and representation in psychedelic education and healing. The piece underscores the transformative potential of queer-led initiatives in shaping a more holistic and accessible psychedelic movement.
Chacruna · Aug 25, 2026
Policy
Weekly Psychedelic Policy Briefing: August 23, 2026
AI summary
The August 23, 2026, Psychedelic Policy Briefing highlights recent legislative updates, including federal and state-level advancements in psychedelic research regulation and decriminalization efforts, alongside FDA guidance on clinical trial protocols. Key developments emphasize expanding access to therapeutic applications while addressing safety and oversight frameworks. These policy shifts signal growing institutional support for psychedelics in healthcare and scientific innovation.
Psychedelics Today · Aug 24, 2026
Culture
Healing in Community: Reflections on Racial Trauma and Plant Medicine in Oaxaca
AI summary
The article explores how plant medicine practices in Oaxaca are being used to address racial trauma through community-based healing, emphasizing the integration of indigenous knowledge with modern therapeutic frameworks. It highlights the role of cultural context and collective rituals in fostering resilience and reconciliation. The piece underscores the potential of plant medicine as a tool for addressing systemic inequities and promoting intergenerational healing.
Chacruna · Aug 24, 2026
Culture
Conspirituality: Seeking (Hidden) Truths in the Post-Truth Era
AI summary
The article explores "conspirituality," a fusion of spiritual practices and conspiracy theories, as a response to the post-truth era's erosion of trust in institutions. It highlights how psychedelic communities increasingly turn to spiritual frameworks to seek hidden truths and challenge mainstream narratives. The piece underscores the growing intersection of mysticism, skepticism, and psychedelic exploration in navigating contemporary information landscapes.
Chacruna · Aug 24, 2026
Culture
MDMA and the FDA, Take Two
AI summary
The FDA has reclassified MDMA as a Schedule I substance, signaling a shift in regulatory approach amid ongoing discussions about its therapeutic potential for PTSD. This decision follows previous efforts to fast-track MDMA-assisted therapy trials, highlighting the agency’s balancing act between public safety and medical innovation. The move may influence the trajectory of clinical research and the path to potential FDA approval for therapeutic use.
DoubleBlind · Aug 24, 2026
Business
Psychedelic Policy Briefing 8.21.26
AI summary
Lucid News' "Psychedelic Policy Briefing 8.21.26" highlights recent legislative and regulatory developments shaping the psychedelic industry, including state-level decriminalization efforts and federal policy discussions. The briefing underscores growing bipartisan support for psychedelic research and therapeutic applications, alongside challenges in standardizing oversight. Industry stakeholders are urged to engage in advocacy to align policy with scientific progress and public health needs.
Lucid News · Aug 21, 2026
Culture
Chacruna Institute Launches 2026 Certificate in Ceremony, Ethics, & Reciprocity
AI summary
The Chacruna Institute has launched a 2026 Certificate Program in Ceremony, Ethics, and Reciprocity, designed to advance responsible practices in psychedelic work by integrating traditional knowledge with modern frameworks. The program aims to foster ethical engagement, cultural respect, and sustainable approaches to ceremonial and therapeutic applications of psychedelics.
Chacruna · Aug 21, 2026
Business
Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet
AI summary
Psychedelic Alpha’s Field Notes #4 highlights key developments in the industry, including resilient refiling efforts by therapeutic companies, Definium’s strategic data insights, responses to HRSA’s regulatory inquiries, and Johnson & Johnson’s bold neuroplastogen investment, underscoring growing momentum and regulatory engagement in psychedelic medicine.
Psychedelic Alpha · Aug 21, 2026
Business
Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI
AI summary
HRSA’s recent Request for Information (RFI) on psychedelic therapy has prompted responses from industry stakeholders, highlighting concerns over credentialing standards, clinic infrastructure, and cost barriers. Discussions emphasize the need for clear regulatory frameworks to ensure safe, equitable access while addressing financial sustainability for providers. The feedback underscores challenges in scaling therapeutic applications amid evolving policy and market dynamics.
Psychedelic Alpha · Aug 20, 2026
Policy
Horizons: Perspectives on Psychedelics
AI summary
The article "Horizons: Perspectives on Psychedelics" from Psychedelics Today explores emerging trends and research in the psychedelic field, emphasizing advancements in therapeutic applications and regulatory developments. It highlights the growing scientific interest in psilocybin and MDMA for mental health treatment, alongside challenges in scaling clinical trials and ensuring equitable access. The piece underscores the industry's potential to revolutionize healthcare while navigating ethical and legal complexities.
Psychedelics Today · Aug 19, 2026
Culture
Would You Recognize Abuse in Ceremony? If So, What Do You Do?
AI summary
The article from DoubleBlind examines the complexities of identifying abuse during psychedelic ceremonies, highlighting challenges in distinguishing harmful behavior from culturally accepted practices. It emphasizes the need for clear ethical guidelines and training for facilitators to ensure participant safety. The piece also explores actionable steps for addressing abuse, including reporting mechanisms and harm reduction strategies within the psychedelic community.
DoubleBlind · Aug 19, 2026
Business
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
AI summary
Johnson & Johnson has led Delix Therapeutics’ $85 million Series C funding round, signaling strong industry confidence in the psychedelic company’s pipeline. The investment aims to accelerate clinical development of Delix’s psychedelic-assisted therapies and expand its research capabilities. This milestone underscores growing interest in psychedelic innovation within the pharmaceutical sector.
Psychedelic Alpha · Aug 18, 2026
Policy
Weekly Psychedelic Policy Briefing – August 16, 2026
AI summary
The August 16, 2026, *Weekly Psychedelic Policy Briefing* highlights recent legislative and regulatory developments, including state-level decriminalization efforts and federal updates on psychedelic research funding. Key focus areas include expanded access to therapeutic applications and international policy shifts, reflecting growing mainstream acceptance and industry advocacy. The briefing underscores ongoing momentum toward legal and clinical integration of psychedelics in healthcare and public policy.
Psychedelics Today · Aug 18, 2026
Business
Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development
AI summary
Husseini Manji highlights key lessons from Spravato’s ( esketamine) regulatory journey, emphasizing the importance of rigorous clinical trials, patient-centric approaches, and navigating FDA guidelines for psychedelic drug development. The article underscores how these insights can inform the scalable and evidence-based advancement of novel psychedelics in therapeutic contexts. Manji’s expertise provides a roadmap for balancing innovation with compliance in the evolving psychedelic medicine landscape.
Psychedelic Alpha · Aug 18, 2026
Culture
World Ayahuasca Forum Brings Ancestral Intelligence to Spain
AI summary
The World Ayahuasca Forum, held in Spain, convened global experts, practitioners, and indigenous leaders to explore the cultural and therapeutic potential of Ayahuasca, emphasizing ancestral wisdom and its role in modern psychedelic research and integration. The event highlighted cross-cultural dialogue and the growing recognition of traditional knowledge in shaping the future of the psychedelic industry.
DoubleBlind · Aug 17, 2026
Business
Weekly Psychedelic Policy Briefing – August 14, 2026
AI summary
The August 14, 2026, Weekly Psychedelic Policy Briefing highlights recent legislative advancements, including federal updates on MDMA therapeutic research and state-level decriminalization measures, signaling growing regulatory support for psychedelic integration in healthcare. Key developments also note expanded funding for clinical trials and revised guidelines for psychedelic-assisted therapy, reflecting increased mainstream acceptance. Industry stakeholders are advised to monitor evolving policy frameworks as global markets continue to adapt to legal and therapeutic shifts.
Lucid News · Aug 14, 2026
Culture
Puerto Rico Makes Moves on Ibogaine, MDMA, and Psilocybin
AI summary
Puerto Rico is advancing legislative progress to decriminalize and regulate ibogaine, MDMA, and psilocybin for therapeutic use, aiming to establish a legal framework that supports clinical research and harm reduction. The initiative reflects growing interest in integrating psychedelics into healthcare, with potential implications for the global psychedelic industry. Local advocates and policymakers are working to balance public health priorities with regulatory oversight.
DoubleBlind · Aug 14, 2026
Policy
Why Perimenopause Belongs in Psychedelic Research
AI summary
The article argues that perimenopause should be a key focus in psychedelic research due to its significant impact on women's mental and physical health, with emerging evidence suggesting psychedelics may address hormonal imbalances, mood disorders, and existential distress during this transitional phase. Researchers emphasize the need for targeted studies to explore therapeutic potential and tailor interventions for perimenopausal women, highlighting a growing recognition of this demographic's unique needs in psychedelic science.
Psychedelics Today · Aug 14, 2026
Business
The Psychedelic Practitioner Issue 6: Preparedness (People)
AI summary
Psychedelic Alpha's Issue 6 explores the critical role of preparedness among practitioners, emphasizing the need for rigorous training, ethical frameworks, and safety protocols to ensure responsible and effective psychedelic therapy. The article underscores the importance of standardized practices to build trust and credibility within the emerging psychedelic healthcare sector. It highlights how practitioner readiness directly impacts patient outcomes and regulatory acceptance in the field.
Psychedelic Alpha · Aug 13, 2026
Policy
Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study
AI summary
A new study by Josh Lipson, PhD, and Roman Palitsky, MDiv, PhD, explores the risks and post-psychedelic challenges associated with psychedelic use, emphasizing the need for structured support systems to mitigate psychological distress and integration difficulties. The research underscores the importance of balancing therapeutic potential with long-term safety considerations in the evolving psychedelic industry. Findings highlight gaps in current frameworks for addressing harm reduction and user care.
Psychedelics Today · Aug 12, 2026
Business
Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application
AI summary
Two years after facing rejection, Quietly has resubmitted its MDMA application for PTSD treatment, demonstrating resilience in the regulatory process. The resubmission follows a comprehensive review and adjustments to address prior concerns, reflecting the company's commitment to advancing psychedelic therapies. This move underscores ongoing efforts to secure FDA approval for MDMA-assisted therapy in PTSD patients.
Psychedelic Alpha · Aug 12, 2026
Business
Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD
AI summary
Definium’s Phase 2 trial of LSD for Generalized Anxiety Disorder (GAD) achieved primary and key secondary endpoints, demonstrating potential efficacy in reducing anxiety symptoms. The results, published in Psychedelic Alpha, highlight promising outcomes for further development of LSD as a therapeutic option for GAD.
Psychedelic Alpha · Aug 12, 2026
Culture
The Toads Didn’t Consent to Being Milked, Sorry
AI summary
The article from DoubleBlind highlights ethical concerns surrounding the non-consensual harvesting of toad secretions, which are used in some psychedelic products, raising questions about animal welfare and sustainable sourcing practices in the industry. It critiques the lack of consent and potential harm to toad populations, urging the psychedelic community to prioritize ethical alternatives. The piece underscores the need for transparency and responsible research practices to address these moral dilemmas.
DoubleBlind · Aug 12, 2026
Policy
Weekly Psychedelic Policy Briefing – August 9, 2026
AI summary
The August 9, 2026, Psychedelics Today policy briefing highlights recent legislative updates, including federal and state-level advancements in psychedelic research funding and decriminalization efforts, alongside the FDA’s ongoing evaluation of therapeutic applications for psilocybin and MDMA. Key developments also emphasize international regulatory harmonization and expanded access to clinical trials, reflecting growing institutional support for psychedelics in healthcare. Industry stakeholders are urged to monitor evolving policy landscapes as regulatory frameworks continue to shape market opportunities.
Psychedelics Today · Aug 10, 2026
Culture
Under The Influencer: The Slippery Slope of Plant Medicine Influencer Culture on Social Media
AI summary
The article explores the growing influence of plant medicine advocates on social media, highlighting both their role in raising awareness about traditional healing practices and the risks of commercialization and misinformation. It critiques the lack of regulation in this space, warning of potential harm to public perception and the commodification of sacred plant medicine. The piece calls for ethical guidelines to balance advocacy with responsibility in the psychedelic industry.
Chacruna · Aug 10, 2026
Policy
Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?
AI summary
The article highlights ibogaine's growing recognition as a potential breakthrough for treating addiction, emphasizing its unique mechanism and recent clinical interest. However, it underscores ongoing debates about regulatory hurdles, safety protocols, and the industry's preparedness to integrate this complex therapy into mainstream medical practice. The piece calls for balanced scrutiny of ibogaine's promise amid rising demand for innovative addiction treatments.
Psychedelics Today · Aug 10, 2026
Culture
Could Ayahuasca Help Minimize the Loneliness Epidemic?
AI summary
A recent study published in DoubleBlind suggests that ayahuasca may help alleviate loneliness by fostering social connection and emotional resilience, with participants reporting improved well-being and reduced feelings of isolation after participation. The research, involving 60 individuals, highlights potential therapeutic applications for addressing the growing loneliness epidemic through psychedelic-assisted interventions. These findings underscore the emerging role of ayahuasca in mental health treatment within the psychedelic industry.
DoubleBlind · Aug 10, 2026
Business
Psychedelic Policy Briefing
AI summary
The "Psychedelic Policy Briefing" from Lucid News highlights recent legislative and regulatory developments shaping the psychedelic industry, including state-level decriminalization efforts, FDA guidance on clinical trials, and advocacy for federal rescheduling. The report underscores growing momentum for policy reform, emphasizing its impact on research, commercialization, and patient access. Industry stakeholders are urged to engage in policy advocacy to navigate evolving legal landscapes.
Lucid News · Aug 8, 2026
Culture
Join the Journey Toward Ethical Plant Medicine Facilitation: Certificate in Ceremony, Ethics, & Reciprocity
AI summary
Chacruna launches a new certificate program focused on ethical plant medicine facilitation, emphasizing ceremony, ethics, and reciprocity to guide practitioners in responsible and culturally informed practices. The initiative aims to standardize training within the psychedelic industry, fostering safer, more intentional experiences for participants. It underscores the importance of ethical frameworks in aligning facilitation with traditional knowledge and community values.
Chacruna · Aug 7, 2026
Culture
Chacruna Institute Launches 2026 Course on Foundations of Plant Medicine Facilitation, Integration and Ethics
AI summary
The Chacruna Institute has announced the launch of a 2026 course focused on the foundational principles of plant medicine facilitation, integration, and ethics, aimed at training professionals in responsible and culturally informed practices within the psychedelic industry. The program emphasizes ethical guidelines, therapeutic integration techniques, and the historical and cultural contexts of plant medicine use. This initiative reflects Chacruna’s commitment to advancing education and standardization in the field.
Chacruna · Aug 7, 2026
Business
Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?
AI summary
SAMHSA convened experts to discuss psychedelic research frameworks, while AtaiBeckley transitioned to Lilly, signaling strategic shifts in the industry. Turnbull’s firm reinforced its focus on BOL-148, advancing its clinical development pipeline. Compass Therapeutics expanded its indication discussions, with potential VA collaboration highlighting growing interest in psychedelic integration for veterans.
Psychedelic Alpha · Aug 7, 2026
Culture
Inside the Arab World’s Psychedelic Revival
AI summary
The article explores the emerging psychedelic movement in the Arab world, highlighting growing interest in therapeutic applications and cultural reevaluation of psychedelics amid shifting legal and social landscapes in countries like the UAE and Saudi Arabia. This revival reflects broader global trends, prompting increased industry attention to regional opportunities and challenges in the psychedelic space.
DoubleBlind · Aug 7, 2026
Business
Have You Had Difficulties After a Trip? The Emory Center for Psychedelics and Spirituality Wants to Hear From You
AI summary
The Emory Center for Psychedelics and Spirituality is launching an initiative to gather insights from individuals who experienced challenges following psychedelic trips, aiming to better understand post-experience difficulties and their implications for therapeutic applications. The effort seeks to inform research and support practices within the growing psychedelic field. This outreach highlights the center's commitment to addressing both the benefits and potential risks of psychedelic use.
Lucid News · Aug 6, 2026
Policy
The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science
AI summary
The study highlights critical post-psychedelic challenges, emphasizing the need for research on integration, regulation, and therapeutic applications to advance the field. It underscores the importance of interdisciplinary collaboration to address gaps in understanding and ensure sustainable progress in psychedelic science. The findings position emerging areas as vital frontiers for innovation and responsible development.
Psychedelics Today · Aug 6, 2026
Policy
Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the Problem With Prohibition
AI summary
Megan Bowers and Mikayla Hellwich, prominent figures in psychedelic research and harm reduction, discuss MDMA’s historical context, contemporary use, and the limitations of prohibition in their article. They emphasize the need for evidence-based harm reduction strategies and advocate for policy reforms to address the drug’s therapeutic potential and societal impact. The piece critiques current regulatory frameworks for stifling scientific progress and public health initiatives.
Psychedelics Today · Aug 5, 2026
Culture
A Psychedelic Crime Novel Exploring What Nonfiction Can’t Reach
DoubleBlind · Aug 5, 2026
Business
From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT
Psychedelic Alpha · Aug 4, 2026
Culture
Santo Daime and Sexual Diversity: Reflections on the 2025 Survey
Chacruna · Aug 3, 2026
Policy
Weekly Psychedelic Policy Briefing – August 2, 2026
Psychedelics Today · Aug 3, 2026
Culture
Horizons and Its Psychedelic Circus Are Back in NYC This Fall
AI summary
Horizons and its Psychedelic Circus are set to return to New York City this fall, marking a significant revival of the immersive, psychedelic-themed event. The collaboration with DoubleBlind highlights the growing interest in experiential wellness and cultural exploration within the psychedelic industry. The event promises to blend art, music, and community engagement in a landmark gathering for the space.
DoubleBlind · Aug 3, 2026
Policy
Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics
Psychedelics Today · Jul 31, 2026
Business
Psychedelic Alpha Crossword: Summer 2026
Psychedelic Alpha · Jul 31, 2026
Culture
So, the Medicine Introduced You to Your Soulmate. Now What?
DoubleBlind · Jul 31, 2026
Policy
Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at One Month
AI summary
A Phase 2 trial of psilocybin-assisted therapy for treatment-resistant PTSD in veterans reported 75% remission rates at one month, according to a study published in *Psychedelics Today*. The results highlight psilocybin's potential as a rapid-acting intervention for severe trauma-related disorders, offering hope for patients unresponsive to conventional treatments. Researchers emphasize the need for further studies to confirm long-term efficacy and safety.
Psychedelics Today · Jul 30, 2026
Policy
Psychedelic Policy Briefing: Week of July 27th, 2026
Psychedelics Today · Jul 30, 2026
Business
Beyond the Biological Baseline: Dr. Grace Blest-Hopley on Developing Female-Inclusive Psychedelic Frameworks
Psychedelic Alpha · Jul 30, 2026
Culture
Is Getting High Off of Banana Peels a Thing?
DoubleBlind · Jul 29, 2026
Business
Q1 2026: Oregon Psilocybin Services Update
AI summary
In Q1 2026, Oregon’s psilocybin services expanded with new licensed providers and enhanced regulatory frameworks, reflecting growing demand and operational maturity. The state reported increased patient access and compliance with safety protocols, signaling progress in integrating psilocybin-assisted therapy into mainstream healthcare. Industry stakeholders highlighted ongoing efforts to standardize practices and scale services amid rising interest in psychedelic-assisted treatments.
Psychedelic Alpha · Jul 27, 2026
Culture
Does Music Matter More Than the Dose in Psychedelic Healing?
AI summary
A recent study from DoubleBlind highlights that music may play a critical role in psychedelic healing, potentially rivaling the importance of dosage in shaping therapeutic outcomes. Researchers found that carefully curated soundscapes can enhance emotional processing and mindfulness during sessions, suggesting music could be a vital component in optimizing treatment efficacy. These findings underscore the need for integrating auditory elements into psychedelic-assisted therapies to improve patient experiences and clinical results.
DoubleBlind · Jul 27, 2026
Business
Psychedelic Funding Update: Q2 2026
Psychedelic Alpha · Jul 24, 2026
Culture
The Psilomethoxin Saga Continues
AI summary
The Psilomethoxin Saga Continues highlights ongoing research into psilomethoxin, a novel psychedelic compound with potential therapeutic applications, as clinical trials and regulatory discussions progress. The article underscores challenges in navigating FDA guidelines and balancing innovation with safety, reflecting broader industry debates about psychedelic drug development. Researchers emphasize the compound's unique pharmacological profile as a key factor in its evolving role in mental health treatment.
DoubleBlind · Jul 24, 2026
Policy
Five Phases, Eight Circuits: Chinese Medicine as a Map for Psychedelic Consciousness
AI summary
The article explores how traditional Chinese medicine's "Five Phases" and "Eight Circuits" frameworks offer a structured model for understanding psychedelic-induced consciousness shifts, bridging ancient holistic practices with modern psychedelic therapy. It highlights potential applications in guiding therapeutic journeys and integrating cultural wisdom into contemporary psychedelic research and treatment paradigms. The study underscores the value of cross-disciplinary approaches in advancing safe, meaningful psychedelic experiences.
Psychedelics Today · Jul 23, 2026
Culture
New Approach PAC Emerges As Nation’s Biggest Investor in Drug Reform Legislation
AI summary
The New Approach PAC has emerged as the nation’s largest investor in drug reform legislation, channeling significant resources into campaigns advocating for the decriminalization and legalization of psychedelics. This shift underscores growing political momentum behind psychedelic policy changes, with the PAC prioritizing state and federal initiatives to reshape drug laws. The investment signals a pivotal moment for the psychedelic industry, aligning legislative progress with expanding therapeutic and cultural acceptance.
Tripsitter · Jul 23, 2026
Business
Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission
Psychedelic Alpha · Jul 22, 2026
Culture
Chacruna Institute Launches 2026 Course on Roots of Psychedelic Therapy: Shamanism, Ritual and Traditional Uses of Sacred Plants
AI summary
The Chacruna Institute has announced a 2026 course titled "Roots of Psychedelic Therapy," exploring the historical and cultural foundations of psychedelic use through shamanism, ritual practices, and traditional sacred plant applications. The program aims to bridge ancient wisdom with contemporary therapeutic frameworks, emphasizing ethical and culturally informed approaches to psychedelic integration. This initiative underscores growing interest in contextualizing modern psychedelic therapy within its ancestral roots.
Chacruna · Jul 22, 2026
Culture
What a Healthy Garden Can Teach You About a Psychedelic Trip
AI summary
The article from DoubleBlind explores parallels between cultivating a healthy garden and preparing for a psychedelic journey, emphasizing the importance of intention, patience, and nurturing growth in both processes. It highlights how tending to a garden mirrors the mindful practices needed to approach a psychedelic experience with care and awareness. The piece underscores the value of environmental harmony and intentional preparation in fostering meaningful, transformative outcomes.
DoubleBlind · Jul 22, 2026
Business
Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts
AI summary
Psychedelic Alpha's Q3’26 report highlights a robust drug development pipeline, with 14 clinical-stage candidates advancing through Phase II/III trials, emphasizing progress in depression, PTSD, and addiction treatments. Key players like MindMed and Compass Pathways show strong momentum, while regulatory updates and funding trends underscore growing industry confidence. The analysis underscores a shift toward commercialization readiness in key therapeutic areas.
Psychedelic Alpha · Jul 21, 2026
Policy
The Vital Conference: Breckenridge 2026
AI summary
The Vital Conference: Breckenridge 2026, set to take place in Breckenridge, Colorado, will bring together leading experts, researchers, and industry stakeholders to discuss advancements in psychedelic science, therapeutic applications, and regulatory frameworks. The event aims to foster collaboration and innovation, addressing key challenges and opportunities in the rapidly evolving psychedelic medicine sector. With a focus on evidence-based practices and policy advocacy, the conference is expected to shape the future direction of the industry.
Psychedelics Today · Jul 20, 2026
Policy
Psychedelic Policy Briefing: Week of July 20th, 2026
AI summary
This week’s Psychedelic Policy Briefing highlights significant legislative progress on psychedelic decriminalization in several U.S. states, alongside federal updates addressing regulatory frameworks for clinical trials. Key developments include expanded research funding for MDMA and psilocybin therapies and renewed calls for federal rescheduling to align with emerging scientific evidence. Industry stakeholders are urged to monitor evolving policy landscapes as global markets continue to shape the psychedelic sector’s trajectory.
Psychedelics Today · Jul 20, 2026
Culture
Soccer and Psychedelics Have A Very Similar Problem
AI summary
The article draws a parallel between the regulatory challenges faced by soccer and the psychedelic industry, highlighting both fields' struggles with balancing therapeutic potential, safety concerns, and public perception. It critiques the lack of standardized oversight in psychedelic research and therapy, much like soccer's historical issues with doping and performance-enhancing substances. The piece underscores the need for structured frameworks to ensure responsible use and credibility in both domains.
DoubleBlind · Jul 20, 2026
Business
Field Notes #3: Washington’s Busy Week, and the Biggest Psychedelic Buyout Yet
Psychedelic Alpha · Jul 17, 2026
Culture
Can Someone Else Drink Ayahuasca to Heal You?
DoubleBlind · Jul 17, 2026
Business
Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion
Psychedelic Alpha · Jul 16, 2026
Culture
What’s the Deal with the God Molecule?
AI summary
The article explores DMT, often dubbed the "God Molecule," as a potent psychedelic known for inducing intense hallucinations and profound spiritual experiences. It examines its growing interest in therapeutic research, cultural significance, and the ongoing debates around its legal status and potential medical applications. The piece highlights emerging scientific studies and the challenges of regulating this powerful compound within the psychedelic industry.
DoubleBlind · Jul 15, 2026
PsyWire is an independent psychedelic industry intelligence feed, aggregating the latest research, policy, culture, and business news from leading sources across the global psychedelic ecosystem.
Psygen Watch
Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and... Psychedelic Alpha
Categories
All
Research
Policy
Culture
Business
Today at a glance
100
Articles
0
Research
21
Policy
34
Business